NCT00301938 - 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2012

Conditions

Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Promyelocytic Leukemia (M3)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Blastic Phase Chronic Myelogenous LeukemiaMyelodysplastic/Myeloproliferative NeoplasmsPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRelapsing Chronic Myelogenous LeukemiaSecondary Acute Myeloid LeukemiaT-cell Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

DRUG

7-hydroxystaurosporine

Given IV

DRUG

perifosine

Given orally

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

21201-1595

University of Maryland Greenebaum Cancer Center, Baltimore

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH